Elizabeth O. Hexner

Hematology

3400 Civic Center Boulevard
West Pavilion, 4th Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 155 publications

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

Journal: medRxiv : the preprint server for health sciences

Published: July 29, 2026

A Donor T-Cell Receptor Structural Signature Determines Alloreactive Potential and Predicts Acute Graft-Versus-Host Disease.

A Donor T-Cell Receptor Structural Signature Determines Alloreactive Potential and Predicts Acute Graft-Versus-Host Disease.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2026

HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.

HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.

Journal: Research square

Published: July 10, 2026

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 09, 2026

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Journal: Blood immunology & cellular therapy

Published: May 15, 2026

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.

Journal: Research square

Published: February 12, 2026

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

Journal: Blood advances

Published: September 29, 2025

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

Journal: Blood advances

Published: September 29, 2025

Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.

Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: August 12, 2025

Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply.

Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply.

Journal: The New England journal of medicine

Published: August 06, 2025

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Journal: Transplantation and cellular therapy

Published: July 31, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Showing 1-12 of 155

Last Updated: 09/26/2026